BriaCell to Present Clinical Findings at the 2020 San Antonio Breast Cancer Symposium®, December 9 – 11
October 06 2020 - 5:30AM
BriaCell Therapeutics Corp.
("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF), a
clinical-stage biotechnology company specializing in targeted
immunotherapy for advanced breast cancer, is pleased to announce
that its lead product candidate, Bria-IMT™, will be featured in a
poster session on December 9 – 11 during the 2020 San Antonio
Breast Cancer Symposium® (SABCS), a virtual event.
The poster will summarize the clinical and
pathological data of the Bria-IMT™ monotherapy study and Phase
I/IIa clinical study of Bria-IMT™ in combination with immune
checkpoint inhibitors including pembrolizumab (KEYTRUDA®;
manufactured by Merck & Co., Inc.), and more recently, Incyte’s
INCMGA00012 (by Incyte Corporation), in advanced breast cancer.
The presentation will
be posted on
https://briacell.com/novel-technology/scientific-publications/.
The details on the poster presentations are as
follows:
Abstract
Number: 1313Presentation
Title: Response to a modified whole tumor cell
targeted immunotherapy in patients with advanced breast cancer
correlates with tumor gradeSession
Date: December 9-11,
2020Program Number: PS17-20Session
Title: Poster Session 17
The abstracts for these presentations will be
available online on the SABCS website at https://www.sabcs.org.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
About SABCS®
Since its inception in 1977, San Antonio Breast
Cancer Symposium (SABCS®) has grown to a program that covers the
latest research on the experimental biology, etiology, prevention,
diagnosis, and treatment of breast cancer and premalignant breast
disease. The Symposium is attended by a large international
audience of researchers, health professionals, physicians,
oncologists, and those with a special interest in breast cancer
from over 90 countries.
To complement the clinical focus of the annual
SABCS®, Baylor College of Medicine became a joint sponsor of SABCS®
in 2005. Additionally, the Cancer Therapy & Research Center
(CTRC) at UT Health Science Center San Antonio and American
Association for Cancer Research (AACR), a prestigious scientific
organization known for its basic, translational and clinical cancer
research, began collaboration with SABC® in 2007. The Symposium was
renamed the CTRC-AACR San Antonio Breast Cancer Symposium.
For additional information on 2020 SABCS®,
please visit: https://www.sabcs.org.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact, this
news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but are
not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this press release. The Company disclaims any intention or
obligation, except to the extent required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024